|
🌎 Our community in the world!
|
|
0
|
301
|
February 6, 2024
|
|
Open-Access Software for Chemical Read-Across
|
|
0
|
189
|
March 12, 2024
|
|
MEGLUMINE (Methylglucamine)
|
|
15
|
1739
|
March 12, 2024
|
|
LOQ for small nitrosamines
|
|
1
|
186
|
March 11, 2024
|
|
🇪🇺 OMCL Network published NDSRIs Analytical Methods
|
|
1
|
615
|
March 11, 2024
|
|
Simple and Practical Method for the Quantitative High-Sensitivity Analysis of N-Nitroso Duloxetine in Duloxetine Drug Products Utilizing LC-MS/MS
|
|
0
|
232
|
March 9, 2024
|
|
AI limit for N-Nitroso Losartan
|
|
4
|
283
|
March 9, 2024
|
|
USP-NF General Notices Revision open for Comments
|
|
0
|
545
|
March 7, 2024
|
|
Read-across Masterclass: How To Facilitate Your Acceptable Intake Limit Setting For Nitrosamines
|
|
0
|
230
|
March 7, 2024
|
|
Updated: IPEC Position Paper on Role of Excipients in Determining N-Nitrosamine Risks for Drug Products
|
|
3
|
588
|
March 7, 2024
|
|
Regulatory Differences between EMA and FDA on Nitrosamines
|
|
0
|
167
|
March 6, 2024
|
|
Define MDD to calculate limit
|
|
39
|
10810
|
March 6, 2024
|
|
Nitrosamines evaluation in transdermal patches
|
|
10
|
1299
|
March 5, 2024
|
|
Ribociclib Succinate NDSRIs limit clarification related
|
|
6
|
478
|
March 5, 2024
|
|
Nitrite Scavengers in Solution and Solid State
|
|
12
|
2005
|
March 5, 2024
|
|
MCC with nitrite levels of 0.1 ppm or less
|
|
4
|
704
|
March 4, 2024
|
|
Role of Carbonyl Compounds for N-Nitrosamine Formation during Nitrosation: Kinetics and Mechanisms
|
|
0
|
264
|
March 2, 2024
|
|
NEWS! New USP Community on qNMR
|
|
0
|
178
|
March 1, 2024
|
|
🇲🇽 Conferencia USP Nitrosaminas en México presencial 21-Marzo
|
|
3
|
447
|
February 29, 2024
|
|
Entidades regulatorias y su postura en el análisis de nitrosaminas en estudios de estabilidad de preparados farmacéuticos
|
|
0
|
146
|
February 28, 2024
|
|
Quality Officer Call for a New approach to Reduce Post Approval Complexity
|
|
0
|
229
|
February 28, 2024
|
|
Regulatory Highlights(OPR&D)
|
|
14
|
1670
|
February 28, 2024
|
|
Is it possible to observe N-nitrosamines formation from oximes? Do you have any reference to support the risk assessment for nitrosamine formation from the reaction of these functional groups in the presence of nitrosating agents? Thank you
|
|
2
|
204
|
February 27, 2024
|
|
🇺🇸 FDA - Updated information on recommended AI for NDSRIs (23/Feb/2024) - Tables 2 & 3
|
|
14
|
1304
|
February 27, 2024
|
|
Anybody using Thermal Energy Analysis for Nitrosamine testing?
|
|
6
|
787
|
February 27, 2024
|
|
AI value for Nitroso Folic acid
|
|
4
|
1369
|
February 26, 2024
|
|
GC-ECD as a method of detection for nitrosamines
|
|
0
|
126
|
February 26, 2024
|
|
In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study Using the Software Program Zeneth
|
|
3
|
255
|
February 24, 2024
|
|
Mechanochemistry: Solid phase nitrosation for reference standards synthesis and impurity investigations?
|
|
1
|
218
|
February 21, 2024
|
|
HESI Open call to Q(SAR) and QM working group
|
|
3
|
492
|
February 20, 2024
|